Thyroid tumors may be more susceptible to treatment with precisely targeted radiation known as stereotactic body radiation therapy rather than conventional radiotherapy, according to a new study published in Thyroid.
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy
.
Many Patients With Rectal Cancer may Not Need Chemoradiotherapy: Study
Patients who are not at high risk of local recurrence can safely undergo surgery without receiving chemoradiotherapy, found study.
Advertisement
‘Animal models of thyroid cancer treated with SBRT had less cancer and lived longer than mice treated with conventional radiation.’
Tweet it Now
"We put patients through toxic treatment for seven weeks when most will only live five months. I'm not sure that's how I would want to spend my time," says Sana Karam, MD, PhD, investigator at the University of Colorado Cancer Center and assistant professor in the CU School of Medicine Department of Radiation Oncology.
The study was made possible by one of Karam's patients.
"It was one of those journeys that reminds you why we are so fortunate to be physicians," Karam says. The patient was only 50 years old at the time of diagnosis. "I treated him with six or seven weeks of radiation only to find that the cancer had already progressed elsewhere in his body. He had six kids, five of them adopted, and at the end of his life one of the only things he could enjoy eating was ice cream, and so they all enjoyed it together."
![Targeted Radiotherapy Offers Good Quality of Life for Women with Early Stage Breast Cancer]( "Targeted Radiotherapy Offers Good Quality of Life for Women with Early Stage Breast Cancer")
Accelerated partial breast irradiation treatment is a valuable alternative for women with early stage breast cancer offering a good quality of life with fewer side effects found a new study.
After her patient passed, the family created a fundraiser called Cream Cancer that accepted small donations from ice cream parlors near where they lived. Eventually the family raised $10,000, which they donated to the Karam lab to fund research to improve treatments for future thyroid cancer patients.
"My biggest thing was seeing if we could replace seven weeks of radiation with a shorter regimen, say three sessions of targeted radiation instead of thirty of conventional radiation," Karam says.
Because the laboratory of CU Cancer Center colleague, Bryan Haugen, MD, holds one of the largest existing batteries of thyroid cancer cell lines, Karam and first co-authors Andy Phan and Ayman Oweida, PhD, were able to show that anaplastic thyroid cancer cells are almost universally resistant to conventional radiotherapy.
Karam wondered if targeted radiation might succeed where conventional radiation failed. In collaboration with the lab of CU researchers Rebecca Schweppe, PhD, and Nikita Pozdeyev, MD, Karam tested these two radiation strategies in mouse models of the disease.
"What we found is that not only is this condensed regimen of targeted radiation equivalent to conventional radiation therapy, but it's actually superior, not only in terms of local control but also distantly," Karam says.
Karam's last point is an important one. A common criticism of targeted radiation is the idea that while it may treat the deposits of cancer at which it is aimed, it may not treat invisible deposits of cancer elsewhere in the body - invisible deposits that might be irradiated as a byproduct of more system-wide, conventional radiation therapy. However, recent work in the Karam lab and elsewhere shows that focused radiation may have a systemic effect.
"It may be that SBRT eradicates the root of the cancer so that it can't continue to send out cells that lead to metastases, or it may be that SBRT wakes up the immune system to the presence of cancer, which helps the immune system combat cancer elsewhere in the body," Karam says.
Whatever the mechanism, mice treated with SBRT had less cancer and lived longer than mice treated with conventional radiation.
The work also found a genetic signature of cancers that resist radiotherapy, namely hyper-activation of the gene CXCR4, which is associated with inflammation and has been shown to aid tumor growth in models of other cancer types.
"Because of our patients who are willing to contribute their tumor tissue to create the cell lines we need for our experiments, and because of our expertise with animal models, Colorado is known to be one of the best places for thyroid cancer research," Karam says.
And because of her patient's motivated family who raised money for research through loose change from ice cream parlors, Karam is able to take another step on the path toward demonstrating more effective, less toxic strategies against anaplastic thyroid cancer.
Source: Eurekalert
"It was one of those journeys that reminds you why we are so fortunate to be physicians," Karam says. The patient was only 50 years old at the time of diagnosis. "I treated him with six or seven weeks of radiation only to find that the cancer had already progressed elsewhere in his body. He had six kids, five of them adopted, and at the end of his life one of the only things he could enjoy eating was ice cream, and so they all enjoyed it together."
Targeted Radiotherapy Offers Good Quality of Life for Women with Early Stage Breast Cancer
Accelerated partial breast irradiation treatment is a valuable alternative for women with early stage breast cancer offering a good quality of life with fewer side effects found a new study.
Advertisement
After her patient passed, the family created a fundraiser called Cream Cancer that accepted small donations from ice cream parlors near where they lived. Eventually the family raised $10,000, which they donated to the Karam lab to fund research to improve treatments for future thyroid cancer patients.
"My biggest thing was seeing if we could replace seven weeks of radiation with a shorter regimen, say three sessions of targeted radiation instead of thirty of conventional radiation," Karam says.
Because the laboratory of CU Cancer Center colleague, Bryan Haugen, MD, holds one of the largest existing batteries of thyroid cancer cell lines, Karam and first co-authors Andy Phan and Ayman Oweida, PhD, were able to show that anaplastic thyroid cancer cells are almost universally resistant to conventional radiotherapy.
Karam wondered if targeted radiation might succeed where conventional radiation failed. In collaboration with the lab of CU researchers Rebecca Schweppe, PhD, and Nikita Pozdeyev, MD, Karam tested these two radiation strategies in mouse models of the disease.
"What we found is that not only is this condensed regimen of targeted radiation equivalent to conventional radiation therapy, but it's actually superior, not only in terms of local control but also distantly," Karam says.
Karam's last point is an important one. A common criticism of targeted radiation is the idea that while it may treat the deposits of cancer at which it is aimed, it may not treat invisible deposits of cancer elsewhere in the body - invisible deposits that might be irradiated as a byproduct of more system-wide, conventional radiation therapy. However, recent work in the Karam lab and elsewhere shows that focused radiation may have a systemic effect.
"It may be that SBRT eradicates the root of the cancer so that it can't continue to send out cells that lead to metastases, or it may be that SBRT wakes up the immune system to the presence of cancer, which helps the immune system combat cancer elsewhere in the body," Karam says.
Whatever the mechanism, mice treated with SBRT had less cancer and lived longer than mice treated with conventional radiation.
The work also found a genetic signature of cancers that resist radiotherapy, namely hyper-activation of the gene CXCR4, which is associated with inflammation and has been shown to aid tumor growth in models of other cancer types.
"Because of our patients who are willing to contribute their tumor tissue to create the cell lines we need for our experiments, and because of our expertise with animal models, Colorado is known to be one of the best places for thyroid cancer research," Karam says.
And because of her patient's motivated family who raised money for research through loose change from ice cream parlors, Karam is able to take another step on the path toward demonstrating more effective, less toxic strategies against anaplastic thyroid cancer.
Source: Eurekalert
High-dose Short-course Radiotherapy: Fast, Safe Treatment for Prostate Cancer Patients
A new radiotherapy treatment for prostate cancer that saves time and was proven safe and effective involves hospital treatment every alternate day for two and half weeks instead of the standard eight weeks radiotherapy.
Advertisement
 How a Patient's Lying Position in Radiotherapy can Affect SurvivalPatient's lying position during radiotherapy treatment for lung or oesophageal cancer can be linked to increase survival chances. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
The presence of painless swelling in the lymph nodes could potentially indicate lymphatic cancer, say experts.
